Please login to the form below

Not currently logged in
Email:
Password:

Merck profits fall 57 per cent

Merck has reported a 57 per cent fall in profits to $1.42bn for the first quarter of 2009, down from $3.33bn in the same reporting period in 2008

Merck has reported a 57 per cent fall in profits to $1.42bn for the first quarter of 2009, down from $3.33bn in the same reporting period in 2008. The US firm said the loss was due primarily to the negative impact of foreign exchange, which resulted in a 3 per cent reduction in global sales for the quarter.

Merck's chairman, president and chief executive officer, Richard Clark, said: "Our first-quarter results in part reflect the impact of the difficult global economy on patients, providers... but we remain on track to meet our full-year earnings guidance."

Despite its first-quarter losses, the company remains confident that its planned $41.1bn merger with Schering-Plough will ensure sustainable growth.

"We believe our planned merger with Schering-Plough will accelerate Merck's transformation into a global healthcare leader built for sustainable growth and success," Richard Clark said.

Until the merger is complete, both entities would continue to operate independently. The merger will double the number of medicines Merck has in phase III development, bringing the total to 18.

27th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics